Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia

Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia

[at noodls] – HAIFA, Israel February 21, 2013 – Pluristem Therapeutics Inc. (NASDAQCM: PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration … more

View todays social media effects on PSTI

View the latest stocks trending across Twitter. Click to view dashboard

See who Pluristem is hiring next, click here to view

Share this post